Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study.

[1]  A. Rossi,et al.  Dose-response effects and time course of effects of inhaled fenoterol on respiratory mechanics and arterial oxygen tension in mechanically ventilated patients with chronic airflow obstruction , 2007, Intensive Care Medicine.

[2]  M. Cazzola,et al.  Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. , 2006, Respiratory medicine.

[3]  M. Cazzola,et al.  Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. , 2006, Respiratory medicine.

[4]  F. Di Marco,et al.  Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease , 2005, Expert opinion on pharmacotherapy.

[5]  J. V. van Noord,et al.  Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD , 2005, European Respiratory Journal.

[6]  M. Cazzola,et al.  Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD. , 2004, Chest.

[7]  B. Make,et al.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.

[8]  M. Cazzola,et al.  Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. , 2004, Pulmonary pharmacology & therapeutics.

[9]  M. Cazzola,et al.  The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. , 2004, Pulmonary pharmacology & therapeutics.

[10]  R. Zuwallack,et al.  Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. , 2003, Chest.

[11]  M. Cazzola,et al.  Long-acting β2 agonists as potential option in the treatment of acute exacerbations of COPD , 2003 .

[12]  J. Wedzicha,et al.  COPD exacerbations: definitions and classifications , 2003, European Respiratory Journal.

[13]  M Cazzola,et al.  A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. , 2003, Respiratory medicine.

[14]  M Cazzola,et al.  Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD , 2003, European Respiratory Journal.

[15]  M. Stanbrook,et al.  Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. , 2002, Archives of internal medicine.

[16]  M. Cazzola,et al.  Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. , 2002, Respiratory medicine.

[17]  D. Ganderton,et al.  Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. , 2002, Respiratory medicine.

[18]  M. Cazzola,et al.  Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. , 2002, Clinical therapeutics.

[19]  M. Cazzola,et al.  Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. , 2001, Respiratory medicine.

[20]  D. Benhamou,et al.  Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). , 2001, Respiratory medicine.

[21]  D. O’Donnell,et al.  Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[22]  R. Stockley,et al.  Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. , 2001, The European respiratory journal.

[23]  W. Graham,et al.  The importance of conducting and reporting pilot studies: the example of the Scottish Births Survey. , 2001, Journal of advanced nursing.

[24]  M. De Salvo,et al.  In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study. , 2001, Chest.

[25]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[26]  M. Cazzola,et al.  Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. , 2001, Pulmonary pharmacology & therapeutics.

[27]  A. Fryer,et al.  Glucocorticoid treatment increases inhibitory m(2) muscarinic receptor expression and function in the airways. , 2001, American journal of respiratory cell and molecular biology.

[28]  B. Grant,et al.  Airway inflammation and etiology of acute exacerbations of chronic bronchitis. , 2000, Chest.

[29]  T. Seemungal,et al.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[30]  M. Littner,et al.  Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[31]  J. V. van Noord,et al.  A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease , 2000 .

[32]  M. Cazzola,et al.  Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. , 1998, Chest.

[33]  K. Nishimura,et al.  Pharmacological Treatment in Acute Exacerbations of Chronic Obstructive Pulmonary Disease , 1998, Drugs & aging.

[34]  Abbas Tashakkori,et al.  Mixed Methodology: Combining Qualitative and Quantitative Approaches , 1998 .

[35]  C. Hirshman,et al.  Glucocorticoid treatment decreases muscarinic receptor expression in canine airway smooth muscle. , 1997, The American journal of physiology.

[36]  F. Maesen,et al.  Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. , 1995, The European respiratory journal.

[37]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.

[38]  A. W. Kemp,et al.  Medical Uses of Statistics. , 1994 .

[39]  T C Chalmers,et al.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. , 1978, The New England journal of medicine.